Novo Nordisk, a leading pharmaceutical company, is making big changes to focus more on obesity and diabetes treatments. Their CEO says this will help the company grow in the long run. To do this, they plan to reduce their workforce by about 9,000 employees, with around 5,000 of those cuts happening in Europe, especially in Denmark. These changes are expected to save the company about DKK 8 billion each year by the end of next year. The company has grown a lot in recent years because of high demand for their popular obesity drug, Wegovy (semaglutide). However, this growth has also made the company more complex and costly to run. The restructuring will help Novo Nordisk invest more in research, sales, and manufacturing. Even though the obesity drug market has slowed down a bit, there is still strong global demand, especially for GLP-1 therapies like Wegovy. Recently, the US FDA approved a generic version of Novo Nordisk’s injectable drug Saxenda (liraglutide), which will compete with other obesity treatments like Eli Lilly’s Zepbound (tirzepatide). Novo Nordisk’s new CEO, Mike Doustdar, says these changes will help the company focus on important research and respond quickly to patient needs. He believes this will lead to sustainable growth and new innovations for people with chronic diseases like diabetes and obesity. The restructuring could also bring big changes to the life sciences industry, as many skilled workers will be available for other companies. Doustdar explained that the changes will allow Novo Nordisk to invest more in research and sales while becoming more flexible to meet patient needs. He emphasized that this will help drive long-term growth and innovation for millions of people with chronic diseases worldwide.